ENDOCAN-1: A feasibility randomised controlled trial of the efficacy of a cannabinoid oral solution in the management of endometriosis-associated pain

开始日期2026-08-01

申办/合作机构-

RBR-3smxct4

/ Not yet recruiting临床2期

Potential effects of cannabinoids in adolescents with attention deficit hyperactivity disorder a double-blind randomized controlled clinical trial

开始日期2026-03-01

申办/合作机构-

NCT07393672

/ Recruiting临床2期IIT

Effects of Hemp-Derived Cannabinoids on Menopause Symptoms

The purpose of the study is to examine the impact of hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.

开始日期2026-02-11

申办/合作机构

Washington State University

100 项与大麻素相关的临床结果

登录后查看更多信息

100 项与大麻素相关的转化医学

登录后查看更多信息

100 项与大麻素相关的专利（医药）

登录后查看更多信息

7,697

项与大麻素相关的文献（医药）

2026-12-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Biosensing technologies for cannabinoid monitoring in pain management: Current methods, clinical needs, and translational challenges

Review

作者: Kim, Jong-Hoon ; Fales, Jessica ; Banik, Shakti

Cannabinoids such as Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD) are increasingly explored for chronic and neuropathic pain management. Still, their clinical use remains limited by variable formulations, uncertain therapeutic ranges, and insufficient concentration-response evidence. Although many cannabinoid detection platforms have been reported, few reviews connect biosensor performance with the clinical requirements of pain management monitoring and therapeutic drug monitoring (TDM). This review summarizes current cannabinoid detection strategies, including conventional analytical methods (such as chromatography, mass spectrometry, and spectroscopy), as well as biosensing platforms such as electrochemical sensors, colorimetric sensors, optical and fluorescence-based platforms, immunoassays, novel material-based sensors, and receptor- or cell-based biological methods. We compare these platforms in terms of target analytes, biological matrices, analytical performance, validation status, and clinical feasibility. Current evidence suggests that portable electrochemical sensors and compact optical/immunoassay platforms are the most promising near-term candidates for point-of-care translation. However, most reported biosensors remain preliminary and require validation in authentic patient samples, comparison with reference methods, improved reproducibility and stability, and stronger links between cannabinoid concentrations, therapeutic response, and adverse effects before routine clinical TDM use.

2026-12-01·IBRO Neuroscience Reports

Modulation of spatial learning and memory by cannabinoid–estrogen interaction in an AD-like cognitive impairment: The role of cannabinoid receptors and BDNF protein

Article

作者: Fanaei, Hamed ; Chahkandi, Mohadeseh ; Mirshekar, Mohammad Ali ; Nadi, Farzaneh

Alzheimer's disease (AD) is an increasingly prevalent neurodegenerative disorder worldwide, with women showing a higher risk of developing the disease. The decline in steroid hormones after menopause may contribute to the increased susceptibility of women to neurodegenerative conditions. In parallel, cannabis-derived compounds have been reported to alleviate certain symptoms associated with neurological disorders. The present study was designed to investigate the effects of marijuana extract on cognitive impairment and hippocampal molecular markers in an ovariectomized AD-like rat model, and to evaluate whether co-administration with estradiol modifies these effects. The marijuana extract used in this study was characterized by HPLC and was found to contain 8.5% Δ9-THC. AD-like cognitive impairment pathology was induced by intra-hippocampal administration of Aβ25-35 in OVX rats. Animals were treated with marijuana extract (60 mg/kg/day, corresponding to approximately 5.1 mg/kg/day Δ9-THC) either alone or in combination with 17β-estradiol (1 mg/kg every 4 days) for 28 days. Cognitive performance was evaluated using the Morris water maze (MWM). In addition, hippocampal CB1/CB2 receptor expression and BDNF protein levels were measured to examine potential molecular associations. Our findings showed that chronic administration of the marijuana extract improved Aβ25-35-induced deficits in spatial learning and memory. Alterations in CB1 receptor expression and BDNF levels accompanied these behavioral effects. Notably, co-treatment with estradiol did not produce a synergistic effect, suggesting a complex interaction between cannabinoid-related and estrogen-related signaling pathways. These preclinical findings suggest that a THC-standardized marijuana extract may exert neuroprotective-like effects in an AD-like cognitive impairment model. However, because the extract was not fully phytochemically characterized and the mechanistic analyses were correlational, the results should be interpreted cautiously. Further studies are needed to clarify the underlying mechanisms and translational relevance of these findings.

2026-12-01·NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Regulation of neural connectivity and oscillations by cannabinoids: A review

Review

作者: Cannizzaro, Carla ; Plescia, Fulvio ; Brancato, Anna ; Marsicano, Giovanni ; Castelli, Valentina ; Lavanco, Gianluca ; Bellocchio, Luigi

Brain oscillations represent frequency-specific neural phenomena essential for coordinating distributed brain activity and supporting cognition. The endocannabinoid system (ECS), particularly via cannabinoid receptor 1 (CB1R), plays a pivotal role in modulating neural oscillations through inhibitory circuit modulation, synaptic plasticity regulation, and long-range connectivity coordination. This review synthesizes current understanding of cannabinoid-oscillation interactions from a primarily mechanistic perspective, organized along a temporal framework: acute cannabinoid effects that directly engage CB1R-mediated circuit modulation; chronic adaptations that produce persistent oscillatory changes outlasting drug exposure; developmental vulnerability during prenatal and adolescent periods when cannabinoid exposure disrupts oscillatory circuit maturation; and aging-related ECS dysfunction in neurodegenerative conditions. Within this temporal structure, we examine specific cognitive domains and clinical conditions where mechanistic insights have translational relevance. Understanding the role of ECS as a modulator of oscillations will improve development of targeted cannabinoid-based therapeutics. We conclude by identifying critical knowledge gaps, including incomplete characterization of cell-type-specific CB1R functions and the mechanistic links between oscillatory dysregulation and specific psychiatric symptoms.

667

项与大麻素相关的新闻（医药）

2026-10-20

·PRNewswire

Rare Cannabinoid Company Publishes Expanded CBN vs. CBD Sleep Guide Featuring Human Research

Updated guide explores falling asleep, nighttime awakenings and next-day fatigue, plus melatonin-free CBN sleep gummies and oils with and without THC HONOLULU, Oct. 20, 2026 /PRNewswire/ -- What is the difference between CBN and CBD for sleep? Can nighttime cannabinoids support restful sleep without added melatonin? Rare Cannabinoid Company answers these questions in its substantially expanded CBN vs. CBD for sleep guide. The guide explains human sleep research in plain language and helps readers compare cannabinoid amounts, product formats and melatonin-free nighttime options. Continue Reading Rare Cannabinoid Company’s melatonin-free CBN Sleep Gummies contain 30 mg CBN and 10 mg CBD per gummy, with zero THC, and are featured in its expanded CBN vs. CBD sleep guide. The updated resource introduces CBN, or cannabinol, as a sleep-focused cannabinoid and CBD, or cannabidiol, as a popular ingredient for calm and relaxation. The guide compares three melatonin-free nighttime formulas: a pure CBN oil, CBN sleep gummies with CBD, and CBN-and-CBD gummies with added THC. Key takeaways from the expanded guide Human CBN research offers encouraging sleep findings: Trials have reported fewer nighttime awakenings and, at a higher studied dose, faster sleep onset. Next-day experience matters: A seven-night trial found reduced nighttime awakenings without increased daytime fatigue. Nighttime formulas offer different experiences: Consumers can choose CBN alone, paired with CBD, or combined with CBD and THC. Melatonin is a separate ingredient: Rare Cannabinoid Company's nighttime products contain no added melatonin. Human research brings CBN sleep benefits into focus A randomized, double-blind, placebo-controlled trial published in Experimental and Clinical Psychopharmacology in 2024 analyzed 293 adults with poor self-rated sleep. Participants receiving 20 mg CBN experienced significantly fewer nighttime awakenings and less overall sleep disturbance than those receiving placebo, without increased daytime fatigue. A 2026 sleep-laboratory trial adds encouraging findings on falling asleep. Published in the August 2026 issue of Journal of Sleep Research , the randomized crossover study compared CBN with placebo in 20 adults. A single 300 mg CBN dose helped participants fall asleep faster and improved their perceived sleep quality on secondary measures. The study's main measure—time awake after initially falling asleep—did not significantly change. The guide explains the research dose and how it differs from the amounts in retail products. Explore melatonin-free CBN oils and gummies The guide compares three Rare Cannabinoid Company nighttime formulas: CBN Rest Oil : A sugar-free, flavorless formula containing 500 mg CBN per bottle in certified organic MCT coconut oil, without THC. CBN Sleep Gummies : Each vegan, huckleberry-flavored gummy contains 30 mg CBN and 10 mg CBD, with zero THC. THC + CBN Sleep Gummies : Each vegan, huckleberry-flavored gummy contains 30 mg CBN, 10 mg CBD and 5 mg hemp-derived delta-9 THC. All three contain no added melatonin. Clearly labeled cannabinoid amounts and accessible batch reports help consumers compare ingredients and formats. The research discussed in the guide examined study preparations rather than these finished products. CBN vs. CBD: common questions answered: What is the difference between CBN and CBD? CBN and CBD are separate cannabinoids found in hemp and cannabis. CBN is increasingly studied for sleep and commonly featured in nighttime products. CBD is widely used for calm and relaxation during the day or evening. Can CBN and CBD be taken together? Yes. Combined formulas provide both cannabinoids in one measured serving. Consumers can also choose pure CBN oil when they prefer a simpler formula. Does a CBN product have to contain THC? No. CBN can be formulated without THC. For adults who enjoy THC's dreamy, euphoric effects, THC-containing options offer a different nighttime experience. THC can cause intoxication. Is CBN the same as melatonin? No. CBN is a cannabinoid; melatonin is a hormone involved in sleep-wake timing. Checking the complete ingredients helps consumers distinguish cannabinoid formulas from products that also contain added melatonin. Readers can explore Rare Cannabinoid Company's CBN sleep gummies and oils to compare nighttime options with and without THC. About Rare Cannabinoid Company Rare Cannabinoid Company is a Honolulu-based hemp wellness brand specializing in rare cannabinoids, including CBN, CBG, CBC, THCV and CBDV. Its range includes gummies, oil tinctures and topicals, with clearly labeled cannabinoid amounts and third-party laboratory reports. SOURCE Rare Cannabinoid Company 21% more press release views with Request a Demo

2026-10-19

·BioSpace

CBIH Announces Expanded Research Strategy at the Intersection of Endocannabinoid Science and Biological Medicine

Houston, Texas--(News - October 19, 2026) - Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced an expansion of its scientific research strategy focused on the intersection of endocannabinoid biology, precision medicine, and the development of intellectual property with potential biomedical applications. "We are witnessing a new era in the history of medicine: an era in which human biology plays a central role in the healing process. The future is no longer solely about treating diseases, but also about discovering how the human body itself can help us overcome them. Humans healing humans," stated Dr. Rosangel Andrades, M.D., CBIH's Director of Research and Development. "Biological medicine as a personalized treatment approach seeks to use each patient's specific biological characteristics to select, adapt, or develop a more precise therapeutic strategy. This may involve analyzing biomarkers, genetic pro cells, antibodies, or other biological components to identify the mechanisms involved in a disease and select the most appropriate intervention. In certain advanced therapies, it is even possible to use a patient's own cells, modify or prepare them in a laboratory, and administer them back to the patient for a specific therapeutic purpose. As a result, medicine is evolving from treatments designed for the general population toward therapeutic strategies guided by each patient's individual biology." CBIH plans to investigate how cannabinoids and the endocannabinoid system interact with molecular and cellular pathways associated with immune regulation, neuroinflammation, reproductive health, chronic pain, metabolic dysfunction, autoimmune diseases, cancer biology, and aging. The Company emphasized that any therapeutic applications arising from these investigations would remain subject to scientific assessment, clinical validation, and applicable regulatory requirements. "Our objective is ambitious but clear: to investigate how endocannabinoid science may contribute to this transformation in biological medicine and open new possibilities for treating complex diseases. We believe that biological medicine represents not only the future of medicine, but also the future of humanity," stated Dr. Jennifer Salguero, a biologist with a Ph.D. in Science from the University of São Paulo, Brazil, and Chief Patent Officer of CBIH. To advance its long-term strategy, CBIH continues preparing scientific studies to develop potentially patentable technologies and strengthen its intellectual property portfolio. Anticipating the proposed broader federal rescheduling of marijuana from Schedule I to Schedule III, the Company intends to explore new research opportunities, strategic partnerships, and licensing agreements with medical, pharmaceutical, and biotechnology organizations. CBIH believes these initiatives could drive future commercialization and long-term shareholder value, subject to research outcomes, regulatory requirements, and successful commercial agreements. FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on . For more information, contact us at: (214) 733-0868 ir@cbih.net Dante Picazo CEO - CBIH Website: X: Instagram: To view the source version of this press release, please visit

2026-10-16

·腾讯网

AI与多组学助力天然产物药物研发创新——清华大学团队 Acta Pharm Sin B 综述

阿司匹林、青蒿素、紫杉醇、长春碱，这些救了无数人的药，祖上都是天然产物。可大概从二十世纪九十年代起，大药企越来越不愿意碰这块矿了。原因很实际：天然成分筛选慢、分离难、结构鉴定繁琐，后面优化更费钱，投入产出比实在算不过来。但技术这东西此消彼长。最近五年，AI（尤其是生成模型和大语言模型）和多组学技术（基因组、转录组、蛋白质组、代谢组）同时成熟，把这条老赛道又炒热了。清华大学自动化系 TCM-X 研究所的李赛团队在 Acta Pharmaceutica Sinica B上发表综述（2026 年 16 卷 7 期，4103–4127 页，DOI: 10.1016/j.apsb.2025.12.030，开放获取），把这件事的方法、案例、数据库家底完整捋了一遍。一、AI 是怎么"读"一个天然化合物的图 1｜天然化合物研究中的 AI 方法总览。图像数据交由卷积神经网络（CNN）处理，图数据交由图神经网络（GNN）处理，序列数据由循环神经网络（RNN）和 Transformer 分析。这些 AI 方法支撑虚拟筛选、分子生成、分子嵌入、性质预测与分子对接等药物发现核心任务，显著推动天然产物领域的药物创新。（图源：Wang et al., Acta Pharm Sin B, 2026）先说分子表示。AI 要理解一个天然化合物，先得把它翻译成机器能读的语言，主流有四套：一维分子指纹，常配自编码器做特征压缩；二维的分子图和结构图，交给 GNN 或卷积模型；三维拓扑结构，捕捉分子的空间构型，用的是 3D 图神经网络；再有就是混合模型，把多种表示用注意力机制揉在一起，预测性能更好。翻译完之后才是正事：虚拟筛选、分子生成、性质预测、分子对接。综述里专门强调，把多模态、多组学数据和化学信息整合起来，能在复杂生物系统里更准地预测化合物活性和药效。二、四大方法域，各管一段图 2｜AI 驱动天然化合物药物发现的方法学框架。四大相互关联的方法域：① 基于物理的相互作用与对接模型，做分子对接和结合亲和力分析；② 关联与预测模型，覆盖药物-靶点、药物-疾病、药物不良反应和药物-药物相互作用；③ 基于生成模型（如变分自编码器）的新化合物设计；④ 天然产物的衍生化与优化，获得治疗潜力更强的衍生物。（图源：Wang et al., Acta Pharm Sin B, 2026）这四个域是全文的骨架，逐个说。第一个域是物理相互作用与对接，解决的是"分子和靶点结合得有多牢"。传统方法计算量大，AI 上来就是提速。V-Dock 直接用SMILES 字符串做输入，绕开昂贵的模拟还保住精度；GEM-Screen 用几何增强的分子表示加主动学习挑候选；DIFFDOCK-PP 更激进，用扩散模型把未结合的蛋白结构一步步变成结合构象；FlowDock则把蛋白序列和配体 SMILES 喂进去，用 ESMFold 预测蛋白结构，靠流匹配直接输出结合模式、置信度和结合亲和力，一步到位。第二个域是关联与预测，管"这个药能治什么病、有什么副作用、和谁一起用会打架"。药物-靶点预测里有 NFSA-DTI、MINN-DTI这类注意力机制模型；药物-疾病预测里，TxGNN 厉害在能给"目前无药可治"的病做零样本预测，DLEPS 则从转录组谱直接预测药效；不良反应预测的 MoLFormer-XL 是深化学语言模型的路子；药物联用预测的 GraphSynergy 在蛋白互作网络上用图卷积捕捉高阶关系。这类模型的共同短板是依赖高质量标注数据，遇到稀有病或新化合物容易抓瞎。第三个域是生成式设计，回答"能不能凭空造一个新分子"。DeepLigBuilder 直接在蛋白结合位点里"长"出分子；DrugDiff 用小分子扩散模型，靠预训练的性质预测器引导生成，想要什么性质调什么参数；SILVR 在隐空间里迭代精修，不用大规模重训。第四个域是衍生化与优化，管"天然产物活性不够怎么改结构"。DerivaPredict 把化学和代谢转化规则塞进深度学习，自动生成衍生物；NIMO 用条件 Transformer 加基序提取，做基于骨架的先导优化；NPGPT 是在天然产物数据上微调过的 GPT 化学语言模型。最夸张的是一个基于 RNN-LSTM 的大规模生成模型，一口气造了 6700 万个类天然产物分子，把天然产物的化学空间硬生生撑大了。三、光说不练假把式：四个已经落地的案例综述 Table 2 盘了四个代表性研究，都走完了"计算预测 + 实验验证"的完整闭环。Merk 团队用循环神经网络，以 54 万多个 ChEMBL 生物活性小分子为训练底料，用天然产物活性模板微调，设计视黄醇 X 受体（RXR）激动剂，最后合成加体外评价，真有两个分子表现出可观的 RXR 调节活性。另一个研究筛 p38α MAP 激酶抑制剂，走的是"机器学习过滤 + 分子对接 + 分子动力学"三级漏斗：先用 MACCS 分子指纹训练的模型过一遍天然产物库，再对接和动力学模拟收口，最后ZINC4260400 和 ZINC8300300 两个天然产物浮出水面，计算机上结合稳定、ADMET 性质也过得去。还有团队用自注意力增强的消息传递神经网络找抗骨质疏松天然产物，体外实验证实候选化合物能抑制破骨细胞分化。海洋天然产物那边，DOGS 算法以 Marinopyrrole A 为起点设计合成分子，再用 SPiDER 预测靶点，一路找到 COX-1 抑制剂，X 射线晶体学给了实锤。四、镜头转向植物：多组学登场图 3｜多组学方法在天然植物研究中的应用总览。组学技术沿 DNA（基因组学）、RNA（转录组学）、蛋白质（蛋白质组学）到代谢物（代谢组学）逐层展开，支撑质量控制、性状鉴定、生物合成通路解析、调控机制理解和中药机制探索，让人对植物来源药物发现获得整体视角。（图源：Wang et al., Acta Pharm Sin B, 2026）天然产物这块，植物是主战场。全世界约30 万种植物里，世卫组织认可有药用价值的约 2.1 万种。多组学在植物上的应用，图 3 画出了层级：从 DNA 到代谢物四层数据，对应到质量控制、性状、合成、调控和中药机制五类问题。质量控制是最见实效的方向。川贝母类药材，用超高效液相色谱-质谱联用加化学计量学分析，找到了物种特异的甾体生物碱标志物，产地和真伪一下子分清；黄芪用 UPLC-QTOF-MS 比较生品和不同炮制品，挖出 15 个标志化合物，解释炮制增效减毒有了分子依据；高丽参的"膨化"工艺比传统蒸制能更快把大人参皂苷转化成活性小皂苷，提取率还更高。代谢基因簇是另一个热点：水稻里通过代谢物全基因组关联分析（mGWAS）找到了一个亚种特异的二萜化合物基因簇，番茄里则锁定了一个合成falcarindiol 的抗病基因簇。五、整合起来：从植物到临床前的完整流水线图 4｜AI 与多组学整合的药用植物药物发现框架。AI 与多组学分析协同应用于天然植物资源：以预测模型做质量控制，以遗传标记刻画性状，识别合成与调控通路，开展药用鉴定，并揭示中药机制。（图源：Wang et al., Acta Pharm Sin B, 2026）图 5｜AI 驱动的植物来源药物发现多组学流水线。从植物性状组学出发，经生物合成基因簇（BGC）发现（AntiSMASH、PRISM）与结构解析（NMR、质谱），进入 AI 驱动的候选优先级排序（DREAMwalk、TxGNN、DLEPS）、合成与衍生化（NIMO、DerivaPredict、NPGPT），最终流向临床前实验（GraphPad Prism、CellProfiler）。（图源：Wang et al., Acta Pharm Sin B, 2026）图 4 是框架图，图 5 是把框架跑通的流水线。这条线上最提气的是合成生物学：科学家把大麻素的完整生物合成通路搬进酵母，从半乳糖这类简单糖直接产出大麻素；抗癌药长春碱的通路在酵母里重构成功；红豆杉紫杉醇生物合成里一个此前未知的酶机制被阐明，为异源生产关键中间体巴卡亭 III 铺平了道路。说白了，以后这些"种不出来、化学合成不起"的珍贵天然产物，可能换成微生物发酵罐来生产。中药是这个框架里的特殊考题。还原论式的"一个药、一个靶点"解释不了方剂，网络药理学于是上位：把药物和疾病放进生物网络里看关系。深度学习框架 HTINet2 把中药知识图谱和临床知识图谱用残差图卷积整合，在青蒿、黄连上验证了靶点预测；TMNP 平台用转录组网络药理学看草药的多尺度效应；李赛团队的 UNIQ 系统则是"AI + 多组学 + 网络药理学"的组合代表。慢性胃炎的中医寒热辨证，也用转录组学找到了各自的分子标志物——热证偏免疫激活，寒证偏免疫抑制，用金红片验证过；胃复春胶囊抗慢性萎缩性胃炎的免疫调节作用，则定位到 Toll 样受体通路和 HES6 表达，体外和大鼠实验都验证了这个结论。六、AI 的弹药库：数据库家底模型再聪明，没数据也是巧妇难为无米之炊。综述把天然产物相关的数据库按三类盘了一遍。天然化合物类里，COCONUT 收了 69.5 万个分子、5.3 万个物种；NPASS 有 9.4万多个天然产物、来自 3.2 万多个生物体，挂在 7700 多个靶点上的活性记录近 96 万条；NP-MRD 存了 28 万个化合物和近 2 万张实验 NMR 谱。植物类里，1K-MPGD收录了 113 个药用植物基因组，PMN 带着 155 个物种的代谢通路数据库。中药类里，HERB 攒了 6743 首方剂、6892 味药材、4.4万个成分；ETCM 收了 4.8 万个方剂；TCMBank 有 9191 味药材、6万多个成分。这些库就是训练和验证 AI 模型的粮草。七、别急着沸腾：五个冷思考文章没一味唱多，局限性讲得挺直白。其一，数据偏科：知名天然产物的文献和数据太多，训练集头重脚轻，模型预测会不自觉偏向"明星分子"，反而可能漏掉真正有价值的小众化合物，得靠数据平衡手段纠偏。其二，植物多组学数据目前只覆盖几百个物种，撑不起大模型。其三，数据泄露和实验条件偏差是暗礁，天然产物数据集里实验条件会引入假相关。其四，天然产物空间和类药化学空间之间存在域迁移问题，模型换个空间就水土不服；立体化学和 3D 构象表示不确定，对含手性中心的化合物影响尤其大。其五，数据库本身有收录缺口，还有许可、知识产权和原住民知识伦理的问题——挖传统医药资源，得尊重当地法律、做好署名、避免剥削传统社区。往后看，作者们判断 LLM 会逐渐唱主角：天然化合物这边，可能从结构驱动模型转向基于 LLM 的模型，还会出现专门服务天然化合物的 AI Agent；植物这边当务之急是多组学数据的大量产出、积累和建库。数据多了，数据库质量高了，模型才准得起来。对药学研究者来说，这篇综述更像一张路线图：AI 负责速度和想象力，多组学负责深度和系统性，两边合流，天然产物这座老矿，值得重新探一遍。参考来源注：本文为文献精读与科学传播用途，所有方法与数据以上述原文为准；文中涉及的技术与候选化合物均处研究阶段，转化为药物尚需完整的临床前与临床研究验证。

100 项与大麻素相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床2期	意大利	Avextra Pharma GmbH	2026-09-01
肌萎缩侧索硬化	临床2期	意大利	Avextra Pharma GmbH	2026-09-01
帕金森病	临床2期	意大利	Avextra Pharma GmbH	2026-09-01
绝经期综合征	临床2期	美国	Washington State University	2026-02-11
更年期综合症	临床2期	美国	Washington State University	2026-02-11
膝关节炎	临床1期	美国	Cannabis Bioscience International Holdings, Inc.	2024-03-20
特应性皮炎	临床阶段不明	荷兰	Incannex Healthcare, Inc.	2023-04-17
银屑病	临床阶段不明	荷兰	Incannex Healthcare, Inc.	2023-04-17
白癜风	临床阶段不明	荷兰	Incannex Healthcare, Inc.	2023-04-17
癫痫	临床前	加拿大	Shackelford Pharma, Inc.	2025-06-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EULAR2022	N/A	银屑病关节炎	-	Cannabinoid (Rheumatoid Arthritis patients using cannabis)	窪遞鬱艱繭鏇構艱顧衊(積鬱鹽鏇鹽鏇獵廠衊壓) = 17.5% of patients with RA using cannabinoids reported side effects not leading to cessation 窪鹹襯衊鏇構顧網鹹觸 (憲壓鹽衊獵選構壓範鏇 )	-	2022-06-01
ISRCTN62942668 (CUPID, Pubmed \| Health Technol Assess)	临床3期	脑疾病 \| 多发性硬化症	498	Δ(9)-tetrahydrocannabinol (Δ(9)-THC)	獵夢蓋構遞艱鏇範蓋範(遞糧艱鏇醖鹹膚膚衊鑰): hazard ratio = 0.92 (95% CI, 0.68 ~ 1.23)	-	2015-02-01
				Placebo
EULAR2011	N/A	肌肉骨骼系统疾病	218	Cannabinoids	壓繭艱網製醖繭鬱醖鬱(築顧選淵積積醖艱夢鏇): P-Value = 5.48 更多	-	2011-05-25
				Placebo
ASCO2009	N/A	周围神经系统疾病	8	Cannabinoids	鹽願醖糧淵範遞醖遞構(醖網鬱襯鏇鑰繭餘鹹窪) = 壓艱衊獵餘艱範獵選築觸繭觸繭齋蓋鏇壓選艱 (鹹遞製憲齋衊壓願範鹽 ) 更多	-	2009-05-20
Pubmed \| Lancet	N/A	肌肉痉挛 \| 多发性硬化症	667	Oral cannabis extract	遞積觸繭糧觸構鹹廠製(壓構選顧膚鏇壓蓋壓鹽) = 願夢蓋膚淵鬱遞獵顧窪壓廠鬱鏇衊壓壓製憲淵 (範築繭窪積選鹽鏇簾製, -1.04 ~ 1.67) 更多	不佳	2003-11-01
				Delta9-tetrahydrocannabinol (Delta9-THC)	遞積觸繭糧觸構鹹廠製(壓構選顧膚鏇壓蓋壓鹽) = 憲衊鹽壓壓鹽壓醖繭憲壓廠鬱鏇衊壓壓製憲淵 (範築繭窪積選鹽鏇簾製, -0.44 ~ 2.31) 更多